Applied Therapeutics, Inc. (APLT)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | - | - | 122 | 144 |
| Total revenue-Research And Development Services | - | - | - | - |
| Research and development | 9,923 | 7,837 | 14,828 | 10,004 |
| General and administrative | 13,175 | 17,688 | 15,037 | 10,580 |
| Total costs and expenses | 23,098 | 25,525 | 29,865 | 20,584 |
| Loss from operations | -23,098 | -25,525 | -29,743 | -20,440 |
| Other expense | -33 | -25 | -21 | -34 |
| Interest income | 364 | 621 | 1,357 | 628 |
| Change in fair value of warrant liabilities | -1,437 | -3,104 | 40,184 | -22,744 |
| Total other income (expense), net | 1,768 | 3,700 | -38,848 | 23,338 |
| Net income (loss) | -21,330 | -21,825 | -68,591 | 2,898 |
| Earnings per share, basic | -0.15 | -0.15 | -0.48 | 0.02 |
| Earnings per share, diluted | -0.15 | -0.15 | -0.48 | -0.13 |
| Weighted average number of shares outstanding, basic | 145,091,474 | 144,787,971 | 144,345,781 | 143,934,239 |
| Weighted-average common stock outstanding - diluted (in shares) | 145,091,474 | 144,787,971 | 144,345,781 | 152,392,748 |